Johnson and Johnson wins baby powder-cancer litigation case in US

Published On 2019-12-23 07:13 GMT   |   Update On 2019-12-23 07:13 GMT

The litigation case (Forrest) in St Louis, Missouri in the US has resulted in a verdict for Johnson & Johnson (JnJ), finding Johnson's baby powder was not the cause of the Vickie Forrest's disease.


New Delhi: The baby powder of Johnson & Johnson(JnJ) is not responsible for a Missouri woman's cancer, a jury in the US has decided in the company's latest win in a litigation case over its famous product.


The litigation case (Forrest) in St Louis, Missouri in the US has resulted in a verdict for Johnson & Johnson (JnJ), finding Johnson's baby powder was not the cause of the Vickie Forrest's disease.


"This is the fourth consecutive verdict in favour of Johnson & Johnson in these cases and the eighth defense verdict this year," a Johnson & Johnson company spokesperson said in a statement.


Read Also: No asbestos found in baby powder test, says Johnson and Johnson


The jury carefully considered the decades of independent clinical evidence, which show Johnson's Baby Powder is safe, does not contain asbestos, and does not cause cancer, it added.


"We know that anyone suffering from cancer is searching for answers, which is why the science and facts on this topic are so important," the statement said.


Read Also: Johnson and Johnson found negligent in landmark vaginal mesh lawsuit in Australia

Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News